Skip to main navigation
Madrigal Pharmaceuticals Madrigal Pharmaceuticals.
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Resmetirom
      • Clinical Trials
      • Publications
  • NASH
    • Overview
    • Patient and HCP Perspectives
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
  • Careers
    • Join the team
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
Search
  • About Us
    • Overview
    • Leadership
    • Board Of Directors
  • Our Programs
    • Overview
    • Resmetirom
      • Clinical Trials
      • Publications
  • NASH
    • Overview
    • Patient and HCP Perspectives
    • Resources
  • Investors & Media
    • Overview
    • Press Releases
    • Events and Presentations
    • Financials and Filings
    • Stock Information
    • Corporate Governance
    • FAQs
  • Careers
    • Join the team
  • Contact
    • General Inquires
    • Medical Information Inquiries
    • Medical Education Grant Submissions
  • Overview
  • Press Releases
  • Events and Presentations
  • Financials and Filings
  • Stock Information
  • Corporate Governance
  • FAQs

Madrigal press releases are available below. Search them by keyword or browse by date.

May 17, 2022
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
May 9, 2022
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
April 28, 2022
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
March 9, 2022
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
February 24, 2022
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
January 31, 2022
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
January 30, 2022
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
January 10, 2022
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer

We are conducting a late-stage clinical development program to demonstrate the benefit of resmetirom to patients with NASH and liver fibrosis.

Learn More
Madrigal Pharmaceuticals. Logo

Madrigal Pharmaceuticals

200 Barr Harbor Drive,
Suite 200

West Conshohocken,
Pennsylvania 19428

  • About Us
  • Our Programs
  • NASH
  • Investors & Media
  • Careers
  • Contact
Madrigal Pharmaceuticals
  • Terms of Use
  • Privacy
  • Cookies
  • CA COMPLIANCE
©2022 Madrigal Pharmaceuticals. All rights reserved.